DOP2017000146A - Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 - Google Patents
Pirazolpiridinaminas como inhibidores de mknk1 y mknk2Info
- Publication number
- DOP2017000146A DOP2017000146A DO2017000146A DO2017000146A DOP2017000146A DO P2017000146 A DOP2017000146 A DO P2017000146A DO 2017000146 A DO2017000146 A DO 2017000146A DO 2017000146 A DO2017000146 A DO 2017000146A DO P2017000146 A DOP2017000146 A DO P2017000146A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compounds
- pirazolpiridinamins
- mknk1
- mknk2
- inhibitors
- Prior art date
Links
- 101000573522 Homo sapiens MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 title 1
- 101001018978 Homo sapiens MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 title 1
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 title 1
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- -1 amine compounds Chemical class 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de pirazolpiridinamina sustituida de fórmula general (I) según se los describe y define aquí, métodos para preparar dichos compuestos, compuestos intermediarios útiles para preparar dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden a dichos compuestos y el uso de dichos compuestos para elaborar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o de angiogénesis, como único agente o en combinación con otros ingredientes activos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199096 | 2014-12-19 | ||
| EP15187501 | 2015-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2017000146A true DOP2017000146A (es) | 2017-07-31 |
Family
ID=54884024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2017000146A DOP2017000146A (es) | 2014-12-19 | 2017-06-19 | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10487092B2 (es) |
| EP (1) | EP3233866B1 (es) |
| JP (1) | JP2018501250A (es) |
| KR (1) | KR20170095985A (es) |
| CN (1) | CN107250138A (es) |
| AU (1) | AU2015366417A1 (es) |
| BR (1) | BR112017013148A2 (es) |
| CA (1) | CA2971242A1 (es) |
| CL (1) | CL2017001615A1 (es) |
| CO (1) | CO2017005968A2 (es) |
| CR (1) | CR20170264A (es) |
| CU (1) | CU20170086A7 (es) |
| DO (1) | DOP2017000146A (es) |
| EA (1) | EA201791363A1 (es) |
| EC (1) | ECSP17038893A (es) |
| GT (1) | GT201700138A (es) |
| IL (1) | IL252686A0 (es) |
| MX (1) | MX2017008161A (es) |
| NI (1) | NI201700078A (es) |
| PE (1) | PE20171104A1 (es) |
| PH (1) | PH12017501133A1 (es) |
| SG (1) | SG11201704916TA (es) |
| SV (1) | SV2017005466A (es) |
| TN (1) | TN2017000258A1 (es) |
| TW (1) | TW201625648A (es) |
| UY (1) | UY36460A (es) |
| WO (1) | WO2016096721A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| WO2017081003A1 (en) * | 2015-11-12 | 2017-05-18 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyridinamines |
| DK3582776T3 (da) | 2017-02-14 | 2024-01-08 | Effector Therapeutics Inc | Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder |
| EP3870178A4 (en) | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | Crystalline forms of mnk inhibitors |
| CN111803476A (zh) * | 2020-08-14 | 2020-10-23 | 华中科技大学协和深圳医院 | 芬戈莫德用于抑制革兰阳性细菌活性的用途 |
| AU2021341508A1 (en) | 2020-09-10 | 2023-05-25 | Precirix N.V. | Antibody fragment against fap |
| US20230000986A1 (en) * | 2021-07-01 | 2023-01-05 | Board Of Regents, The University Of Texas System | Mnk inhibitors and eif4e phosphorylation modulation to treat inflammatory pain in the aged |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| JP4712702B2 (ja) * | 2003-07-24 | 2011-06-29 | バイエル・シエリング・フアーマ・アクチエンゲゼルシヤフト | 高増殖性疾患を処置するために有用な置換されたテトラヒドロベンゾチエノピリミジンアミン化合物 |
| EP1799653B1 (en) | 2004-08-20 | 2013-03-20 | Bayer Intellectual Property GmbH | Condensed thienopyrimidine derivatives for the treatment of cancer |
| EP3239154A1 (en) | 2011-01-10 | 2017-11-01 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN104507950B (zh) * | 2012-05-21 | 2017-03-22 | 拜耳医药股份有限公司 | 噻吩并嘧啶 |
| CN104470931B (zh) * | 2012-05-21 | 2016-10-26 | 拜耳医药股份有限公司 | 取代的苯并噻吩并嘧啶 |
| CN104781251B (zh) * | 2012-11-08 | 2016-12-14 | 百时美施贵宝公司 | 可作为激酶调节剂的经双环杂环取代的吡啶基化合物 |
| CN105189518A (zh) * | 2013-02-01 | 2015-12-23 | 拜耳制药股份公司 | 取代的噻吩并吡啶和其药物用途 |
-
2015
- 2015-12-14 EA EA201791363A patent/EA201791363A1/ru unknown
- 2015-12-14 MX MX2017008161A patent/MX2017008161A/es unknown
- 2015-12-14 CR CR20170264A patent/CR20170264A/es unknown
- 2015-12-14 KR KR1020177019615A patent/KR20170095985A/ko not_active Withdrawn
- 2015-12-14 EP EP15813014.6A patent/EP3233866B1/en active Active
- 2015-12-14 TN TN2017000258A patent/TN2017000258A1/en unknown
- 2015-12-14 CN CN201580076266.7A patent/CN107250138A/zh active Pending
- 2015-12-14 PE PE2017001100A patent/PE20171104A1/es not_active Application Discontinuation
- 2015-12-14 CU CUP2017000086A patent/CU20170086A7/es unknown
- 2015-12-14 US US15/537,694 patent/US10487092B2/en active Active
- 2015-12-14 CA CA2971242A patent/CA2971242A1/en active Pending
- 2015-12-14 AU AU2015366417A patent/AU2015366417A1/en not_active Abandoned
- 2015-12-14 WO PCT/EP2015/079587 patent/WO2016096721A1/en not_active Ceased
- 2015-12-14 SG SG11201704916TA patent/SG11201704916TA/en unknown
- 2015-12-14 JP JP2017533275A patent/JP2018501250A/ja active Pending
- 2015-12-14 BR BR112017013148-0A patent/BR112017013148A2/pt not_active IP Right Cessation
- 2015-12-18 UY UY0001036460A patent/UY36460A/es not_active Application Discontinuation
- 2015-12-18 TW TW104142845A patent/TW201625648A/zh unknown
-
2017
- 2017-06-05 IL IL252686A patent/IL252686A0/en unknown
- 2017-06-16 PH PH12017501133A patent/PH12017501133A1/en unknown
- 2017-06-16 CO CONC2017/0005968A patent/CO2017005968A2/es unknown
- 2017-06-19 DO DO2017000146A patent/DOP2017000146A/es unknown
- 2017-06-19 SV SV2017005466A patent/SV2017005466A/es unknown
- 2017-06-19 NI NI201700078A patent/NI201700078A/es unknown
- 2017-06-19 GT GT201700138A patent/GT201700138A/es unknown
- 2017-06-19 CL CL2017001615A patent/CL2017001615A1/es unknown
- 2017-06-20 EC ECIEPI201738893A patent/ECSP17038893A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20171104A1 (es) | 2017-08-07 |
| CU20170086A7 (es) | 2017-11-07 |
| CL2017001615A1 (es) | 2018-03-16 |
| EP3233866A1 (en) | 2017-10-25 |
| BR112017013148A2 (pt) | 2019-11-19 |
| KR20170095985A (ko) | 2017-08-23 |
| IL252686A0 (en) | 2017-08-31 |
| PH12017501133A1 (en) | 2017-11-27 |
| US20180162877A1 (en) | 2018-06-14 |
| GT201700138A (es) | 2018-12-06 |
| SV2017005466A (es) | 2018-10-02 |
| TW201625648A (zh) | 2016-07-16 |
| US10487092B2 (en) | 2019-11-26 |
| CN107250138A (zh) | 2017-10-13 |
| UY36460A (es) | 2016-07-29 |
| EP3233866B1 (en) | 2021-04-21 |
| CR20170264A (es) | 2017-07-21 |
| ECSP17038893A (es) | 2017-07-31 |
| AU2015366417A1 (en) | 2017-06-29 |
| JP2018501250A (ja) | 2018-01-18 |
| TN2017000258A1 (en) | 2018-10-19 |
| CA2971242A1 (en) | 2016-06-23 |
| MX2017008161A (es) | 2017-09-18 |
| WO2016096721A1 (en) | 2016-06-23 |
| CO2017005968A2 (es) | 2017-10-20 |
| NI201700078A (es) | 2017-09-22 |
| SG11201704916TA (en) | 2017-07-28 |
| EA201791363A1 (ru) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17007538A (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| CR20170264A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CR20160433A (es) | Nuevos compuestos | |
| NI201600006A (es) | Pirazolo-piridinaminas sustituidas | |
| NI201500118A (es) | Imidazopiridazinas sustituidas | |
| CU20160072A7 (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| DOP2016000268A (es) | Compuestos de azol amidosustituidos como inhibidores de tnks1 y/o tnks2 | |
| CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
| UY36983A (es) | Pirazolopiridinaminas sustituidas | |
| UY37032A (es) | Compuestos de heteroarilbenzimidazol | |
| UY34630A (es) | Imidazopiridazinas sustituidas con amino |